Search Result

Results for "

fluid pressure

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Carbonic Anhydrase (4) Drug Derivative (1) Endothelin Receptor (3) Fluorescent Dye (1) Natriuretic Peptide Receptor (NPR) (1) Prostaglandin Receptor (1) Reference Standards (2) Renin (1)
By Research Areas:	Cardiovascular Disease (9) Endocrinology (3) Metabolic Disease (1) Neurological Disease (4)

Inhibitors & Agonists

Peptides

Isotope-Labeled Compounds

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-B0588

Brinzolamide 5+ Cited Publications AL-4862	Carbonic Anhydrase	Cardiovascular Disease Others Neurological Disease
Brinzolamide (AL-4862) is a selective carbonic anhydrase II inhibitor with anIC₅₀ value of 3.2 nM. Brinzolamide hydrochloride reduces intraocular pressure (IOP) by inhibiting ciliary CA-II and decreasing atrial fluid secretion. Brinzolamide can be used in glaucoma disease research .

HY-15195

Avosentan Ro 67-0565; SPP-301	Endothelin Receptor	Cardiovascular Disease Endocrinology
Avosentan (Ro 67-0565; SPP-301) is an orally active endothelin (ETA) receptor antagonist. Avosentan can block the ETA receptor, thereby reducing vascular contraction and exerting a renal protective effect. Avosentan inhibits vascular contraction caused by ET-1 and alleviates the reduction in retinal and optic nerve head blood flow induced by it, lowering intraocular pressure in the glaucoma monkey model. Avosentan non-specifically blocks ETB receptors at high doses, inhibiting ETB-mediated diuresis and natriuresis, and may cause fluid retention. Avosentan can be used to reduce proteinuria with diabetic nephropathy, but induces significant fluid overload and congestive heart failure .

HY-W002450

L-Cyclohexylalanine	Drug Derivative	Cardiovascular Disease
L-Cyclohexylalanine is an amino acid derivative. L-Cyclohexylalanine modifies an atrial natriuretic peptide, regulates homeostasis of body fluid and blood pressure homeostasis and vasodilation activity .

HY-P5792

Atrial natriuretic peptide (3-28) (human) ANP (3-28) (human)	Endothelin Receptor	Cardiovascular Disease Metabolic Disease
Atrial natriuretic peptide (3-28) (human) (ANP (3-28) (human)) is a peptide hormone that is synthesized and secreted by the atrial myocardium. Atrial natriuretic peptide (3-28) (human) is involved in the regulation of blood pressure, fluid balance, and electrolyte homeostasis .

HY-P2491

Atrial Natriuretic Peptide (1-28), human, porcine, Biotin-labeled	Fluorescent Dye	Cardiovascular Disease Endocrinology
Atrial Natriuretic Peptide (1-28), human, porcine, Biotin-labeled, one of three mammalian natriuretic peptides (NPs), has endocrine effects on fluid homeostasis and blood pressure. Atrial Natriuretic Peptide has the potential for cardiovascular diseases research .

HY-106113

Ditekiren U 71038	Renin	Cardiovascular Disease
Ditekiren (U 71038) is a pseudohexapeptide renin inhibitor. Renin is an enzyme that plays a crucial role in regulating blood pressure and fluid balance. By inhibiting the activity of renin, ditekiren slows down the formation of angiotensin II, a potent vasoconstrictor that can raise blood pressure. Ditekiren can be used for research in the field of blood pressure reduction .

HY-B0588A

Brinzolamide hydrochloride AL-4862 hydrochloride	Carbonic Anhydrase	Neurological Disease
Brinzolamide (AL-4862) hydrochloride is a selective carbonic anhydrase II inhibitor with an IC₅₀ value of 3.2 nM. Brinzolamide hydrochloride reduces intraocular pressure (IOP) by inhibiting ciliary CA-II and decreasing atrial fluid secretion. Brinzolamide hydrochloride can be used in glaucoma disease research .

HY-138206

Prostaglandin E1 isopropyl ester PGE1 isopropyl ester	Prostaglandin Receptor	Cardiovascular Disease
Prostaglandin E1 isopropyl ester is an isopropyl ester form of prostaglandin E1 (HY-B0131). Prostaglandin E1 isopropyl ester exhibits a faster penetration flux than prostaglandin E1 .

HY-120147

Ethiazide	Natriuretic Peptide Receptor (NPR)	Cardiovascular Disease
Ethiazide is a thiazole diuretic which inhibits renal reabsorption of sodium and water, thereby increasing urine excretion, reducing fluid retention, and lowering blood volume and blood pressure. Ethiazide can be used for cardiovascular research .

HY-B0588AS

Brinzolamide-d5 hydrochloride AL-4862-d₅ hydrochloride	Carbonic Anhydrase	Neurological Disease
Brinzolamide-d₅ (hydrochloride) is the deuterium labeled Brinzolamide hydrochloride . Brinzolamide (AL-4862) hydrochloride is a selective carbonic anhydrase II inhibitor with an IC₅₀ value of 3.2 nM. Brinzolamide hydrochloride reduces intraocular pressure (IOP) by inhibiting ciliary CA-II and decreasing atrial fluid secretion. Brinzolamide hydrochloride can be used in glaucoma disease research .

HY-B0588R

Brinzolamide (Standard) AL-4862 (Standard)	Reference Standards Carbonic Anhydrase	Others Neurological Disease
Brinzolamide (Standard) is the analytical standard of Brinzolamide. This product is intended for research and analytical applications. Brinzolamide (AL-4862) is a selective carbonic anhydrase II inhibitor with anIC₅₀ value of 3.2 nM. Brinzolamide hydrochloride reduces intraocular pressure (IOP) by inhibiting ciliary CA-II and decreasing atrial fluid secretion. Brinzolamide can be used in glaucoma disease research .

HY-15195R

Avosentan (Standard) Ro 67-0565 (Standard); SPP-301 (Standard)	Reference Standards Endothelin Receptor	Cardiovascular Disease Endocrinology
Avosentan (Standard) is the analytical standard of Avosentan (HY-15195). This product is intended for research and analytical applications. Avosentan is an orally active endothelin (ETA) receptor antagonist. Avosentan can block the ETA receptor, thereby reducing vascular contraction, and exerting a renal protective effect. Avosentan inhibits vascular contraction caused by ET-1 and alleviates the reduction in retinal and optic nerve head blood flow induced by it, lowering intraocular pressure in the glaucoma monkey model. Avosentan non-specifically blocks ETB receptors at high doses, inhibiting ETB-mediated diuresis and natriuresis, and may cause fluid retention. Avosentan can be used to reduce proteinuria with diabetic nephropathy, but induces significant fluid overload and congestive heart failure.

Cat. No.	Product Name	Target	Research Area

HY-W002450

L-Cyclohexylalanine	Drug Derivative	Cardiovascular Disease
L-Cyclohexylalanine is an amino acid derivative. L-Cyclohexylalanine modifies an atrial natriuretic peptide, regulates homeostasis of body fluid and blood pressure homeostasis and vasodilation activity .

HY-P5792

Atrial natriuretic peptide (3-28) (human) ANP (3-28) (human)	Endothelin Receptor	Cardiovascular Disease Metabolic Disease
Atrial natriuretic peptide (3-28) (human) (ANP (3-28) (human)) is a peptide hormone that is synthesized and secreted by the atrial myocardium. Atrial natriuretic peptide (3-28) (human) is involved in the regulation of blood pressure, fluid balance, and electrolyte homeostasis .

HY-P2491

Atrial Natriuretic Peptide (1-28), human, porcine, Biotin-labeled	Fluorescent Dye	Cardiovascular Disease Endocrinology
Atrial Natriuretic Peptide (1-28), human, porcine, Biotin-labeled, one of three mammalian natriuretic peptides (NPs), has endocrine effects on fluid homeostasis and blood pressure. Atrial Natriuretic Peptide has the potential for cardiovascular diseases research .

HY-W342021

Thr-Leu	Peptides	Others
Thr-Leu is a dipeptide composed of threonine and leucine. Thr-Leu can be hydrolyzed in the peritoneal cavity to generate constituent amino acids, thereby increasing the osmotic pressure of the dialysate. Thr-Leu can be used for the kinetic study of amino acid-based peritoneal dialysis fluids .

HY-W342021R

Thr-Leu (Standard)	Peptides	Others
Thr-Leu is a dipeptide composed of threonine and leucine. Thr-Leu can be hydrolyzed in the peritoneal cavity to generate constituent amino acids, thereby increasing the osmotic pressure of the dialysate. Thr-Leu can be used for the kinetic study of amino acid-based peritoneal dialysis fluids .

Cat. No.	Product Name	Chemical Structure

HY-B0588AS

Brinzolamide-d5 hydrochloride
Brinzolamide-d₅ (hydrochloride) is the deuterium labeled Brinzolamide hydrochloride . Brinzolamide (AL-4862) hydrochloride is a selective carbonic anhydrase II inhibitor with an IC₅₀ value of 3.2 nM. Brinzolamide hydrochloride reduces intraocular pressure (IOP) by inhibiting ciliary CA-II and decreasing atrial fluid secretion. Brinzolamide hydrochloride can be used in glaucoma disease research .

Brinzolamide-d5 hydrochloride

Brinzolamide-d₅ (hydrochloride) is the deuterium labeled Brinzolamide hydrochloride . Brinzolamide (AL-4862) hydrochloride is a selective carbonic anhydrase II inhibitor with an IC₅₀ value of 3.2 nM. Brinzolamide hydrochloride reduces intraocular pressure (IOP) by inhibiting ciliary CA-II and decreasing atrial fluid secretion. Brinzolamide hydrochloride can be used in glaucoma disease research .

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

Name
Email *

	Sorry, but the email address you supplied was invalid.